Navigation Links
StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
Date:10/22/2008

MENLO PARK, Calif., Oct. 22 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing systems for Enabling Regenerative Medicine(TM), announced today that it has signed an agreement with Hospira, Inc. (NYSE: HSP) to develop and commercialize StemCor's proprietary System for the harvest of bone marrow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO)

StemCor will develop the System for Hospira, and Hospira will manage the clinical trial program, leading to commercialization. The System has 510(k) clearance from the U.S. Food and Drug Administration and CE Mark in Europe, and Hospira plans to initiate post-approval clinical use studies in early 2009 to support product launch thereafter. Under the agreement, Hospira will market the device to Oncologists, Hematologists and other physicians specializing in bone marrow transplantation.

"We are excited to develop this System's potential in collaboration with Hospira, a leading global specialty pharmaceutical and medication delivery company," said Vartan Ghazarossian, Ph.D., President and CEO of StemCor. "This is a specialized market that varies from country to country, and we are pleased to have a strong distribution partner in both the U.S. and around the world."

Andrew Robbins, Director of Strategy and Ventures at Hospira, said, "This agreement is a step forward as Hospira seeks to provide innovative products for the oncology market. Hospira is excited to provide a new device to facilitate bone marrow harvest, with the goal of improving the donor experience."

About StemCor's Product

StemCor's proprietary System is designed to rapidly and easily harvest bone marrow in a minimally invasive manner, in the outpatient setting, and without general anesthesia. The System consists of an access guide, a powered handle that drives a flexible atraumatic shaft through which marrow is aspirated, and an integrated marrow collection container. The shaft gains access to the bone marrow cavity through the access guide to allow the removal of bone marrow through a single entry site. This is in contrast to the current practice of bone marrow aspiration through the repeated insertion of a needle into multiple sites in the iliac crest of the hip, which usually requires general anesthesia, an operating room, and multiple clinical personnel. Preclinical studies demonstrated the ability of the System to safely harvest large volumes of marrow with greater stem cell activity than is contained in standard needle aspirates.

About StemCor Systems

StemCor Systems is a privately held medical device company located in the San Francisco Bay Area. The company's initial product is a proprietary, minimally-invasive bone marrow collection system. The technology was licensed exclusively from Stanford University.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquarted in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.

Contact: Vartan Ghazarossian, Ph.D.

President and CEO

StemCor Systems, Inc.

650-321-6884

Vartan@StemCorSystems.com


'/>"/>
SOURCE StemCor Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
2. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
3. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
4. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
7. Martek Signs Multi-Year Sole-Source Supply Agreement With Hero
8. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
9. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
10. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
11. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):